Detalhe da pesquisa
1.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol
; 23(12): 1571-1582, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370716
2.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1458-1467, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543613
3.
Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic.
Oncologist
; 26(4): e694-e703, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539583
4.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat
; 190(2): 265-275, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34476645
5.
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.
Future Oncol
; 16(27): 2059-2073, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32598185
6.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326029
7.
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
Future Oncol
; 14(9): 849-859, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527957
8.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657003
9.
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
Oncologist
; 19(6): 608-15, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24794159
10.
Drug waste minimization as an effective strategy of cost-containment in oncology.
BMC Health Serv Res
; 14: 57, 2014 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24507545
11.
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
EClinicalMedicine
; 70: 102501, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685923
12.
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
BMC Cancer
; 13: 164, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23537313
13.
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
EClinicalMedicine
; 59: 101931, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256095
14.
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Clin Cancer Res
; 29(24): 5217-5226, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888299
15.
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Breast Cancer Res Treat
; 132(3): 843-51, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21750964
16.
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Anticancer Drugs
; 23(3): 326-34, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22129512
17.
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature.
Curr Oncol
; 29(12): 9630-9639, 2022 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36547170
18.
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.
NPJ Breast Cancer
; 8(1): 1, 2022 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013314
19.
Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?
Front Oncol
; 12: 885992, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747814
20.
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Target Oncol
; 17(6): 615-625, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36152144